In this edition:
KEYNOTE-A18: Pembrolizumab + CCRT for high-risk LACC
GCIG INTERLACE: Induction chemotherapy + chemoradiation in LACC
innovaTV: Tisotumab vedotin in second-/thirdline recurrent/metastatic cervical cancer
AtTEnd: carboplatin/paclitaxel + atezolizumab in advanced/recurrent endometrial carcinoma
DUO-E: carboplatin/paclitaxel + durvalumab + olaparib in advanced/recurrent endometrial cancer
NRG GY018: mechanisms of MMR loss in endometrial cancer
RUBY: survival outcomes according to molecular subgroup
Neoadjuvant pembrolizumab in dMMR endometrial cancer
ICON8B: dose-dense paclitaxel + bevacizumab + carboplatin in high-risk epithelial ovarian cancer
FLAMES: senaparib in newly diagnosed advanced ovarian cancer
ANITA: atezolizumab + platinum-based chemotherapy & maintenance niraparib in late-relapsing recurrent ovarian cancer
Gemcitabine-based therapy in ovarian clear cell carcinoma
Please login below to download this issue (PDF)